AAPL333.02+11.36 (+3.53%) ▲|ABBV259.36+2.44 (+0.95%) ▲|ABT103.06+2.31 (+2.29%) ▲|ACN146.99+8.25 (+5.95%) ▲|ADBE225.11+12.94 (+6.10%) ▲|AMAT536.25-26.55 (-4.72%) ▼|AMD521.95-17.74 (-3.29%) ▼|AMGN376.04+4.54 (+1.22%) ▲|AMT166.67+2.02 (+1.23%) ▲|AMZN232.11-1.55 (-0.66%) ▼|AVGO381.92-10.55 (-2.69%) ▼|AXP326.17-14.67 (-4.30%) ▼|BA209.52+0.29 (+0.14%) ▲|BAC62.05+0.77 (+1.26%) ▲|BKNG177.46+4.63 (+2.68%) ▲|BLK1,055.67+18.51 (+1.78%) ▲|BMY62.09+0.58 (+0.94%) ▲|BNY158.91-1.20 (-0.75%) ▼|BRK-B494.93+4.08 (+0.83%) ▲|C132.19+0.31 (+0.24%) ▲|CAT888.73-5.81 (-0.65%) ▼|CL90.75+0.67 (+0.74%) ▲|CMCSA22.30+0.38 (+1.71%) ▲|COF202.84+2.88 (+1.44%) ▲|COP120.26+0.06 (+0.05%) ▲|COST935.03+8.97 (+0.97%) ▲|CRM163.66+6.73 (+4.29%) ▲|CSCO114.17+1.41 (+1.25%) ▲|CVS107.74+0.85 (+0.80%) ▲|CVX194.79+0.37 (+0.19%) ▲|DE628.16+18.14 (+2.97%) ▲|DHR191.50-1.00 (-0.52%) ▼|DIS94.85+2.02 (+2.18%) ▲|DUK130.52+1.26 (+0.97%) ▲|EMR147.94+3.04 (+2.10%) ▲|FDX314.96-0.66 (-0.21%) ▼|GD386.75+4.96 (+1.30%) ▲|GE353.73+4.73 (+1.36%) ▲|GEV1,014.75-16.44 (-1.59%) ▼|GILD129.31-1.55 (-1.18%) ▼|GM82.64+1.97 (+2.44%) ▲|GOOG319.09+0.75 (+0.24%) ▲|GOOGL319.74+2.05 (+0.65%) ▲|GS1,061.23-13.49 (-1.26%) ▼|HD332.98+8.27 (+2.55%) ▲|HON243.15-3.12 (-1.27%) ▼|IBM214.19+7.54 (+3.65%) ▲|INTC92.32-7.91 (-7.89%) ▼|INTU296.33+14.80 (+5.26%) ▲|ISRG337.50+5.48 (+1.65%) ▲|JNJ263.40+4.13 (+1.59%) ▲|JPM353.21+3.31 (+0.95%) ▲|KO82.25+1.08 (+1.33%) ▲|LIN512.28+5.96 (+1.18%) ▲|LLY1,196.03+10.16 (+0.86%) ▲|LMT582.60+14.01 (+2.46%) ▲|LOW207.64+5.72 (+2.83%) ▲|LRCX305.21-14.57 (-4.56%) ▼|MA539.66+9.37 (+1.77%) ▲|MCD264.76+1.96 (+0.75%) ▲|MDLZ60.52+0.47 (+0.78%) ▲|MDT83.21+1.20 (+1.46%) ▲|META595.19-10.91 (-1.80%) ▼|MMM172.62+3.03 (+1.79%) ▲|MO72.99+0.91 (+1.26%) ▲|MRK131.07+0.59 (+0.45%) ▲|MS214.48-0.70 (-0.33%) ▼|MSFT381.70+0.12 (+0.03%) ▲|MU920.95-69.26 (-6.99%) ▼|NEE89.78-0.01 (-0.01%) ▼|NFLX70.09+1.20 (+1.74%) ▲|NKE41.70+0.71 (+1.73%) ▲|NOW98.78+6.84 (+7.44%) ▲|NVDA206.84-1.92 (-0.92%) ▼|ORCL114.99-5.05 (-4.21%) ▼|PEP136.64+1.69 (+1.25%) ▲|PFE24.54-0.04 (-0.16%) ▼|PG147.41+1.53 (+1.05%) ▲|PLTR122.92-0.45 (-0.36%) ▼|PM193.00+1.88 (+0.98%) ▲|QCOM166.97-4.14 (-2.42%) ▼|RTX212.79+3.63 (+1.74%) ▲|SBUX103.25+0.04 (+0.04%) ▲|SCHW101.97+0.36 (+0.35%) ▲|SO97.25+0.65 (+0.67%) ▲|SPG229.78+4.58 (+2.03%) ▲|T24.13+1.17 (+5.10%) ▲|TMO568.26-4.06 (-0.71%) ▼|TMUS180.09+9.67 (+5.67%) ▲|TSLA313.03-6.66 (-2.08%) ▼|TXN279.58-5.41 (-1.90%) ▼|UBER65.94-2.97 (-4.31%) ▼|UNH420.74-2.82 (-0.67%) ▼|UNP307.32+2.99 (+0.98%) ▲|UPS114.79+0.69 (+0.60%) ▲|USB63.97+0.64 (+1.01%) ▲|V355.74+4.14 (+1.18%) ▲|VZ46.38+2.56 (+5.84%) ▲|WFC86.31+0.12 (+0.14%) ▲|WMT109.47+1.07 (+0.99%) ▲|XOM156.94+0.05 (+0.03%) ▲|AAPL333.02+11.36 (+3.53%) ▲|ABBV259.36+2.44 (+0.95%) ▲|ABT103.06+2.31 (+2.29%) ▲|ACN146.99+8.25 (+5.95%) ▲|ADBE225.11+12.94 (+6.10%) ▲|AMAT536.25-26.55 (-4.72%) ▼|AMD521.95-17.74 (-3.29%) ▼|AMGN376.04+4.54 (+1.22%) ▲|AMT166.67+2.02 (+1.23%) ▲|AMZN232.11-1.55 (-0.66%) ▼|AVGO381.92-10.55 (-2.69%) ▼|AXP326.17-14.67 (-4.30%) ▼|BA209.52+0.29 (+0.14%) ▲|BAC62.05+0.77 (+1.26%) ▲|BKNG177.46+4.63 (+2.68%) ▲|BLK1,055.67+18.51 (+1.78%) ▲|BMY62.09+0.58 (+0.94%) ▲|BNY158.91-1.20 (-0.75%) ▼|BRK-B494.93+4.08 (+0.83%) ▲|C132.19+0.31 (+0.24%) ▲|CAT888.73-5.81 (-0.65%) ▼|CL90.75+0.67 (+0.74%) ▲|CMCSA22.30+0.38 (+1.71%) ▲|COF202.84+2.88 (+1.44%) ▲|COP120.26+0.06 (+0.05%) ▲|COST935.03+8.97 (+0.97%) ▲|CRM163.66+6.73 (+4.29%) ▲|CSCO114.17+1.41 (+1.25%) ▲|CVS107.74+0.85 (+0.80%) ▲|CVX194.79+0.37 (+0.19%) ▲|DE628.16+18.14 (+2.97%) ▲|DHR191.50-1.00 (-0.52%) ▼|DIS94.85+2.02 (+2.18%) ▲|DUK130.52+1.26 (+0.97%) ▲|EMR147.94+3.04 (+2.10%) ▲|FDX314.96-0.66 (-0.21%) ▼|GD386.75+4.96 (+1.30%) ▲|GE353.73+4.73 (+1.36%) ▲|GEV1,014.75-16.44 (-1.59%) ▼|GILD129.31-1.55 (-1.18%) ▼|GM82.64+1.97 (+2.44%) ▲|GOOG319.09+0.75 (+0.24%) ▲|GOOGL319.74+2.05 (+0.65%) ▲|GS1,061.23-13.49 (-1.26%) ▼|HD332.98+8.27 (+2.55%) ▲|HON243.15-3.12 (-1.27%) ▼|IBM214.19+7.54 (+3.65%) ▲|INTC92.32-7.91 (-7.89%) ▼|INTU296.33+14.80 (+5.26%) ▲|ISRG337.50+5.48 (+1.65%) ▲|JNJ263.40+4.13 (+1.59%) ▲|JPM353.21+3.31 (+0.95%) ▲|KO82.25+1.08 (+1.33%) ▲|LIN512.28+5.96 (+1.18%) ▲|LLY1,196.03+10.16 (+0.86%) ▲|LMT582.60+14.01 (+2.46%) ▲|LOW207.64+5.72 (+2.83%) ▲|LRCX305.21-14.57 (-4.56%) ▼|MA539.66+9.37 (+1.77%) ▲|MCD264.76+1.96 (+0.75%) ▲|MDLZ60.52+0.47 (+0.78%) ▲|MDT83.21+1.20 (+1.46%) ▲|META595.19-10.91 (-1.80%) ▼|MMM172.62+3.03 (+1.79%) ▲|MO72.99+0.91 (+1.26%) ▲|MRK131.07+0.59 (+0.45%) ▲|MS214.48-0.70 (-0.33%) ▼|MSFT381.70+0.12 (+0.03%) ▲|MU920.95-69.26 (-6.99%) ▼|NEE89.78-0.01 (-0.01%) ▼|NFLX70.09+1.20 (+1.74%) ▲|NKE41.70+0.71 (+1.73%) ▲|NOW98.78+6.84 (+7.44%) ▲|NVDA206.84-1.92 (-0.92%) ▼|ORCL114.99-5.05 (-4.21%) ▼|PEP136.64+1.69 (+1.25%) ▲|PFE24.54-0.04 (-0.16%) ▼|PG147.41+1.53 (+1.05%) ▲|PLTR122.92-0.45 (-0.36%) ▼|PM193.00+1.88 (+0.98%) ▲|QCOM166.97-4.14 (-2.42%) ▼|RTX212.79+3.63 (+1.74%) ▲|SBUX103.25+0.04 (+0.04%) ▲|SCHW101.97+0.36 (+0.35%) ▲|SO97.25+0.65 (+0.67%) ▲|SPG229.78+4.58 (+2.03%) ▲|T24.13+1.17 (+5.10%) ▲|TMO568.26-4.06 (-0.71%) ▼|TMUS180.09+9.67 (+5.67%) ▲|TSLA313.03-6.66 (-2.08%) ▼|TXN279.58-5.41 (-1.90%) ▼|UBER65.94-2.97 (-4.31%) ▼|UNH420.74-2.82 (-0.67%) ▼|UNP307.32+2.99 (+0.98%) ▲|UPS114.79+0.69 (+0.60%) ▲|USB63.97+0.64 (+1.01%) ▲|V355.74+4.14 (+1.18%) ▲|VZ46.38+2.56 (+5.84%) ▲|WFC86.31+0.12 (+0.14%) ▲|WMT109.47+1.07 (+0.99%) ▲|XOM156.94+0.05 (+0.03%) ▲|
20.3 C
New York
Sunday, July 26, 2026

Tag: score

Concept Study Identifies Potential Refining Pathway at Shaakichiuwaanaan to Battery-Grade Lithium Carbonate

Study highlights potential to produce a value-added lithium chemical at site, offering further opportunities to reduce logistics intensity over time and aligning with Canada's...

Concept Study Identifies Potential Refining Pathway at Shaakichiuwaanaan to Battery-Grade Lithium Carbonate

Study highlights potential to produce a value-added lithium chemical at site, offering further opportunities to reduce logistics intensity over time and aligning with Canada's...

Celldex Presents Long-Term Barzolvolimab Results Demonstrating Sustained Off-Treatment Improvement in Angioedema in Patients with CSU at the European Academy of Allergy and Clinical Immunology...

HAMPTON, N.J., June 14, 2026 (GLOBE NEWSWIRE) -- Celldex (NASDAQ:CLDX) announced today the presentation of long-term results from the Phase 2 study of barzolvolimab in a flash talk session at the European Academy of Allergy and Clinical Immunology (EAACI) Annual Meeting in Istanbul, Türkiye. The data presented demonstrated that barzolvolimab treatment results in rapid, significant, and durable improvements in angioedema in patients with chronic spontaneous urticaria (CSU) refractory to antihistamines. These results were sustained off-treatment, seven months after completion of barzolvolimab dosing (Week 76). The data continue to demonstrate barzolvolimab’s potential to shift the goal of CSU treatment from symptom control to disease modification and further support the ongoing Phase 3 trials of barzolvolimab in CSU.

Upstream Bio Presents New Responder Analyses Demonstrating Clinically Meaningful Improvements in CRSwNP in Significant Majority of Participants Treated with Verekitug in the Phase 2...

– Verekitug, administered once every three months, led to clinically meaningful improvements in nasal polyp score (NPS) in approximately 80% of participants –

Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress

The combination of selinexor plus ruxolitinib met the first co-primary endpoint demonstrating a statistically significant improvement of spleen volume reduction (SVR35) of 49.8% for...

Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress

The combination of selinexor plus ruxolitinib met the first co-primary endpoint demonstrating a statistically significant improvement of spleen volume reduction (SVR35) of 49.8% for...

Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress

The combination of selinexor plus ruxolitinib met the first co-primary endpoint demonstrating a statistically significant improvement of spleen volume reduction (SVR35) of 49.8% for...

Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor (NEXPOVIO®) Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026...

FLORENCE, Italy and NEW YORK, June 14, 2026 (GLOBE NEWSWIRE) -- The Menarini Group (“Menarini”), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. (“Stemline”), a wholly-owned subsidiary of the Menarini Group focused on bringing transformational oncology treatments to cancer patients, announced that new data related to the pivotal Phase 3 SENTRY trial will be presented as a late-breaking oral at The European Hematology Association (EHA) 2026 Congress.

 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026

 -- Patients with PWS treated with setmelanotide therapy (N=17) achieved clinically meaningful BMI or BMI z-score reductions, reductions in fat mass with preservation of lean mass, and improvements in hyperphagia and anxiety measures --   

-- Positive results reinforce rationale for Phase 3 development of MC4R agonism in PWS --

A Guide to Football Betting with Zizobet Bookmakers – Non Gamstop Fast Registration – World Cup 2026

New York City, June 12, 2026 (GLOBE NEWSWIRE) --

A new reputable online betting site in 2026 for players to bet on the FIFA World Cup 2026. Zizobet Casino has a fast registration process and offers a great welcome bonus for new players. Please read our detailed review.

PlanetBids Named to Inc.’s 2026 Best Workplaces List for the Second Consecutive Year

ORMOND BEACH, Fla., June 12, 2026 (GLOBE NEWSWIRE) -- PlanetBids today announced that it has been named to Inc.’s 2026 Best Workplaces list for the second straight year. Each year, Inc. Magazine honors American companies that have built exceptional workplaces and vibrant cultures that support their teams and businesses, whether in-person, remote, or hybrid.

Inc. evaluates and measures applicants on elements such as management effectiveness, perks, professional development, and overall company culture. A detailed employee survey conducted over a period of March 4 to March 13, 2026 and a study of each company’s benefits over a period of November 2025 to February 2026, both conducted by Quantum Workplace, determine a company’s overall score. PlanetBids is honored to be included among the 507 companies recognized this year.

Founded in 2000, PlanetBids has been a fully remote/hybrid-optional company since 2020, with offices in Studio City, Calif. and Ormond Beach, Fla. and team members located across 19 states. The company was acquired by Capstreet, a Houston-based private equity firm, from co-founders Arpie and Alan Zavian, in October 2023.

"Being recognized by Inc. as one of the Best Workplaces for the second consecutive year is an incredible honor and a reflection of what makes PlanetBids truly special: our people," says David DiGiacomo, Chief Executive Officer at PlanetBids. "As a primarily remote company, we believe we’re proving that culture isn’t built by sharing an office; it’s built by sharing a mission, values, trust, and a commitment to each other’s success. This recognition belongs to every member of our team who shows up each day with passion, curiosity, and a desire to make a difference for our customers and one another."

PlanetBids champions a culture built around five core values that guide how the team works, grows, and supports one another:

Geckos Games Launches Momentum – The Most Adrenaline-Charged Live Sports Game Ever Built

THRILLZZ Free Social Sportsbook launches as exclusive first brand - debuting on the opening day of the world's biggest Soccer tournamentZero latency real-time gameplay...

Ataccama Named a 2026 Best Places to Work Company by the Boston Business Journal

A 96-engagement score and 100% highly engaged workforce reflect a culture united around helping enterprises ensure their data is ready to fuel AI
A 96-engagement score and 100% highly engaged workforce reflect a culture united around helping enterprises ensure their data is ready to fuel AI

IFS Named a Customers’ Choice in the Gartner® Voice of the Customer for Cloud ERP for Product-Centric Enterprises for the Fourth Consecutive Year

IFS is the only vendor to receive the Customers' Choice recognition in the 2026 Gartner Peer Insights Voice of the Customer for Cloud ERP...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsScore